| Document |
Document Title |
|
WO/2017/066965A1 |
Compounds used for treatment of inflammation and sepsis, or pharmaceutically acceptable salts or analogs thereof are disclosed.
|
|
WO/2017/068348A1 |
A new crystalline form of tetraacetylethylenediamine (Form II) is prepared by melt crystallisation of the known crystalline form of tetraacetylethylenediamine (Form I) and is characterised by, inter alia, powder X-ray diffraction, FT-IR ...
|
|
WO/2017/070536A1 |
Compounds having the general structure of Formula (I) and pharmaceutical compositions thereof are described for treating non-alcoholic steatohepatitis and other liver disease.
|
|
WO/2017/067837A1 |
Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, A, X and Y are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparatio...
|
|
WO/2017/065495A2 |
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...
|
|
WO/2017/061759A1 |
The present invention relates to a method for synthesizing an acylglycinate salt, and a human body detergent composition using the same and, more particularly, to a method for synthesizing an acylglycinate salt having an improved reactio...
|
|
WO/2017/061624A1 |
This disclosure provides: a first site that is a terminal structure capable of binding a decoy molecule, for hydroxylating a hydrocarbon-based substrate by a cytochrome P450 monooxygenase, to a substrate-binding site of the cytochrome P4...
|
|
WO/2017/057433A1 |
The present invention addresses the problem of developing a novel methodology that provides superior analysis of enantiomers. This problem is solved by means of an enantiomer analysis method comprising (1) to (3) as follows. (1) A mixtur...
|
|
WO/2017/056832A1 |
Provided is an active-light-sensitive or radiation-sensitive composition that contains (A) a compound having two or more of the structures represented by general formula (1), the compound not having an acid crosslinking group, and (B) a ...
|
|
WO/2017/053360A1 |
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a periph...
|
|
WO/2017/049172A1 |
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...
|
|
WO/2017/049176A1 |
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...
|
|
WO/2017/043626A1 |
Provided is a method for producing an optically active 4-carbamoyl-2,6-dimethylphenylalanine derivative, which is a compound useful as an intermediate for a medicine, in a simple manner and with high efficiency. 4-carbamoyl-2,6-dimethylb...
|
|
WO/2017/043175A1 |
Provided is a near-infrared absorbing curable composition which is capable of forming a cured film that has excellent infrared light shielding properties and visible light transparency, while exhibiting excellent heat resistance and ligh...
|
|
WO/2017/041139A1 |
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
|
|
WO/2017/037596A1 |
The present application relates to amorphous solid dispersion of LCZ-696 with one or more pharmaceutically acceptable carrier. Specifically, the present application relates to amorphous solid dispersion of LCZ-696 with one or more pharma...
|
|
WO/2017/036357A1 |
Provided are a cathepsin K inhibitor and application thereof, and specifically is a compound having a structure represented by formula (I) and being used to treat or prevent a cathepsin dependent disease. In particular, the cathepsin is ...
|
|
WO/2017/037661A1 |
The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions com...
|
|
WO/2017/032384A1 |
The present invention relates to a composition comprising a compound of formula (I) (a 4-(3-ethoxy-2 hydroxypropoxy) acrylanilide) derivative) and its use in a method of treating cough.
|
|
WO/2017/033212A1 |
The invention provides a process for preparing sacubitril. The present invention also provides a novel salt of sacubitril and its crystalline form. The invention further provides crystalline N-(3-carboxy-1- oxopropyl)-(4S)-(p-phenylpheny...
|
|
WO/2017/028745A1 |
Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C.elegans and mice.
|
|
WO/2017/029362A1 |
The present invention relates to processes, process steps and intermediates useful in the asymmetric bisamidation of malonic ester derivatives wherein the new processes, process steps and intermediates are, for example, useful in the pre...
|
|
WO/2017/026944A1 |
An organogelator compound is provided. The organogelator compound has Formula (I): wherein R1, R2, and R3 are independently selected from the group consisting of H, halogen, a substituted or unsubstituted C1-C20 alkyl, a substituted or u...
|
|
WO/2017/020125A1 |
The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. Th...
|
|
WO/2017/024009A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
|
WO/2017/020841A1 |
Disclosed is a pharmaceutical composition containing a specific crystalline powder of LCZ696. The crystalline powder of LCZ696 having a specific powdery feature satisfies a requirement of a preparation process and can be used to produce ...
|
|
WO/2017/018751A1 |
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...
|
|
WO/2017/017232A1 |
The present invention relates to a use of a tertiary amine as buffer in sample preparation, preferably for mass spectrometry and/or UV/vis spectroscopy, wherein the sample comprises proteins, polypeptides and/or peptides, and said sample...
|
|
WO/2017/016883A1 |
The present invention relates to a process for preparing cyclopentene compounds of formula (I) wherein the variables have the meaning as defined in the description, by cyclisation under basic conditions of a ketone of formula (II) which ...
|
|
WO/2017/018750A1 |
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...
|
|
WO/2017/017193A1 |
The invention relates to novel dissymmetric N,N-dialkylamides having formula (I), wherein R represents a straight or branched alkyl group at C8 to C15. The invention also relates to a method for synthesising said N,N-dialkylamides, and t...
|
|
WO/2017/015451A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the functi...
|
|
WO/2017/012963A1 |
The invention relates to polymerizable fatty acid derivative monomers with terminal olefinic double bonds, polymers containing said monomers, to the production of said polymers, mixtures of polymers and monomers, to the use of the polyme...
|
|
WO/2017/012917A1 |
Several methods for the preparation of an amorphous powder comprising a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions c...
|
|
WO/2017/014013A1 |
A compound represented by formula (1). For example, R1 represents an alkyl group having 1-15 carbon atoms; MES represents a mesogenic group having at least one ring; Sp1 represents a single bond or an alkylene group having 1-10 carbon at...
|
|
WO/2017/015301A1 |
The invention provides a compound of formula (I): (I) wherein R1-R4 have any of the values defined in the specification, as well as compositions comprising a compound of formula (I) and methods for treating diseases (e.g. cancer).
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2017/012379A1 |
The present invention provides an oxalic acid monoamide ligand, and uses thereof in a coupling reaction of a copper-catalyzed aryl halogen substitute. Specifically, the present invention provides uses of a compound represented by formula...
|
|
WO/2017/011232A1 |
Non-cyclic amide or thioamide based ionic liquids and methods of making them are disclosed.
|
|
WO/2017/006048A1 |
The invention relates to compounds of formula I (I) or the salts thereof, and to the use of same in the pharmaceutical, cosmetic or agrofood industry.
|
|
WO/2017/007204A1 |
An oseltamivir analog and nanoparticles having the analog bound thereto, of the present invention, strongly bind to oseltamivir-resistant influenza viruses, and thus, the use of the same can allow detection of oseltamivir-resistant influ...
|
|
WO/2017/002494A1 |
Provided is a method for producing an N-vinyl carboxylic acid amide, which comprises a thermal decomposition step wherein an N-(2-oxyethyl)carboxylic acid amide is thermally decomposed in the presence of a solid catalyst. It is preferabl...
|
|
WO/2017/003107A1 |
The present invention relates to a method for preparing a benzoic acid amide compound in a high yield by presenting a novel method for preparing a benzyl amine compound to be used as a reactant and delimiting the reaction condition of ea...
|
|
WO/2017/004143A1 |
Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c a...
|
|
WO/2017/004525A1 |
N-benzylbenzamides that act as dual soluble soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor γ (PPARy) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, in...
|
|
WO/2016/208682A1 |
Provided are: a compound which makes it possible to produce an oxazoledicarboxylic acid compound on an industrial scale at low cost; a method for producing the compound; and a method for producing an oxazoledicarboxylic acid compound usi...
|
|
WO/2016/209765A1 |
A pharmaceutical composition containing a benzhydrylsulfinylacetamide antidepressant, and either or both of an SSRI uptake inhibitor and/or a stimulating antidepressant has been shown to be effective in ameliorating symptoms of dementia,...
|
|
WO/2016/204079A1 |
Provided is a charge-transporting varnish which comprises an amide compound containing fluorine atoms and represented by formula (1) and a charge-transporting substance. [In the formula, Ar1 represents a group represented by any of formu...
|
|
WO/2016/203017A1 |
The present invention relates to a process for preparing a procatalyst for polymerization of olefins, comprising contacting a magnesium-containing support with a halogen-containing titanium compound, a first internal electron donor repre...
|
|
WO/2016/201354A1 |
Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective amount of at least one inhibitor of tryptophan 2, 3-dioxygenase (TDO) and/or indoleamine 2, 3-dioxygenase (IDO), optiona...
|
